GlassScriptPhysician profile
Beth Schramm
NPI 1083706881
$2,916.33
in general payments reported to CMS, 2019-2025
15 companies · $722 in 2025
The $722 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $169 · 2021: $275 · 2022: $441 · 2023: $735 · 2024: $364 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $586.63 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $523.93 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Biotissue Holdings INC. | $314.18 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $219.41 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $211.76 | 2024-2025 | |
| Oyster Point Pharma, INC. | $203.59 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $192.84 | 2021-2025 | Precision 1, Tryptyr, Eysuvis |
| Novartis Pharmaceuticals Corporation | $159.66 | 2019-2023 | |
| Abbvie INC. | $136.14 | 2022 | |
| Allergan, INC. | $99.74 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $94.54 | 2025 | Xdemvy |
| Optos, INC. | $70.83 | 2022 | |
| Menicon America INC | $39.64 | 2019 | |
| Kala Pharmaceuticals, INC. | $37.30 | 2021 | |
| Dompe US, INC. | $26.14 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Schramm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.